A decisive advantage of an MCT4 isoform-specific inhibitor for ccRCC therapeutic use would be the highly restricted expression in normal body tissues in comparison to the ubiquitously expressed MCT1 11. The gene discussed is SLC16A3; the disease is nonpapillary renal cell carcinoma.